Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 to 5 (canceled)

6. (currently amended) An isolated antibody ~~The antibody of claim 1~~, wherein said antibody ~~further~~ comprises ~~complementarity determining regions (CDRs) having the following sequences~~:

a) an antibody heavy chain having CDRs comprising CDR1 corresponding to amino acids 31 to 35 of SEQ ID NO:1 ~~(aa 31-35)~~, CDR2 corresponding to amino acids 50 to 66 of SEQ ID NO:1, ~~(aa 50-66)~~ and CDR3 corresponding to amino acids 98 to 108 ~~(aa 98-108)~~ of SEQ ID NO:1, wherein amino acid 31 can be asparagine or serine, amino acid 66 can be glycine or can be deleted, and amino acid 104 can be glutamic acid or aspartic acid; and

b) an antibody light chain having CDRs comprising CDR1 corresponding to amino acids 18 to 34 or 24 to 34 of SEQ ID NO:2~~(aa 18-34 or aa 24-34)~~, CDR2 corresponding to amino acids 50 to 56 of SEQ ID NO:2, ~~(aa 50-56)~~ and CDR3 corresponding to amino acids 89 to 98~~(aa 89-98)~~ of SEQ ID NO:2, wherein amino acid 96 can be proline or isoleucine, and amino acid 98 can be phenylalanine or can be deleted.

7. (currently amended) An isolated antibody ~~according to claim 1~~, wherein said antibody ~~further~~ comprises:

a) a heavy chain comprising a heavy chain variable region ~~(VH)~~ of SEQ ID NO:1, wherein amino acid ~~(aa)~~ 30 is serine or arginine, ~~aa~~ amino acid 31 is asparagine or serine, ~~aa~~ amino acid 94 is histidine or tyrosine and ~~aa~~ amino acid 104 is aspartic acid

or glutamic acid, wherein said heavy chain further ~~comprising~~ comprises a human heavy chain constant region ~~(CH)~~; and

b) a light chain comprising a light chain variable region ~~(VL)~~ of SEQ ID NO:2, wherein ~~aa~~ amino acid 96 is proline or isoleucine, ~~aa~~ amino acid 100 is proline or glutamine, ~~aa~~ amino acid 103 is arginine or lysine, ~~aa~~ amino acid 104 is valine or leucine and ~~aa~~ amino acid 105 is aspartic acid or glutamic acid, ~~and~~ wherein said light chain further ~~comprising~~ comprises a human light chain constant region~~(CL)~~.

8. (currently amended) The antibody of claim 7, wherein the heavy chain amino acids 30, 31, 94 and 104 are the following:

a) ~~aa~~ amino acid 30 is arginine ~~Arg~~, ~~aa~~ amino acid 31 is asparagine ~~Asn~~, ~~aa~~ amino acid 94 is tyrosine ~~Tyr~~ and ~~aa~~ amino acid 104 is aspartic acid ~~Asp~~, or

b) ~~aa~~ amino acid 30 is arginine ~~Arg~~, ~~aa~~ amino acid 31 is serine ~~Ser~~, ~~aa~~ amino acid 94 is tyrosine ~~Tyr~~ and ~~aa~~ amino acid 104 is aspartic acid ~~Asp~~, or

c) ~~aa~~ amino acid 30 is serine ~~Ser~~, ~~aa~~ amino acid 31 is asparagine ~~Asn~~, ~~aa~~ amino acid 94 is histidine ~~His~~ and ~~aa~~ amino acid 104 is glutamic acid ~~Glu~~.

9. (currently amended) The antibody of claim 7, wherein the light chain amino acids 96, 100, 103, 104 and 105 are the following:

a) ~~aa~~ amino acid 96 is proline ~~Pro~~, ~~aa~~ amino acid 100 is proline ~~Pro~~, ~~aa~~ amino acid 103 is lysine ~~Lys~~, ~~aa~~ amino acid 104 is valine ~~Val~~ and ~~aa~~ amino acid 105 is aspartic acid ~~Asp~~, or

b) ~~aa~~ amino acid 96 is isoleucine ~~Ile~~, ~~aa~~ amino acid 100 is glutamine ~~Gln~~, ~~aa~~ amino acid 103 is arginine ~~Arg~~, ~~aa~~ amino acid 104 is leucine ~~Leu~~ and ~~aa~~ amino acid 105 is glutamic acid ~~Glu~~.

10. (currently amended) The antibody of claim ~~1~~ 6 wherein said antibody is obtainable from a hybridoma cell line consisting of the group selected from <IGF-1R> HuMab Clone 1a, <IGF-1R> HuMab Clone 23 and <IGF-1R HuMab Clone 8.

11. (currently amended) A composition comprising the antibody of claim ~~1~~ 6 and a pharmaceutically acceptable carrier or diluent.

Claims 12 to 22 (canceled)

23. (currently amended) A composition comprising the antibody of claim ~~6~~ 7 and a pharmaceutically acceptable carrier or diluent.

24. (new) A composition comprising the antibody of claim 8 and a pharmaceutically acceptable carrier or diluent.

25. (new) A composition comprising the antibody of claim 9 and a pharmaceutically acceptable carrier or diluent.

26. (new) A composition comprising the antibody of claim 10 and a pharmaceutically acceptable carrier or diluent.